

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
San Francisco Regional Office
90 Seventh Street, Suite 5-300 (5W)
San Francisco, CA 94103-6706



DIVISION OF MEDICAID & CHILDREN'S HEALTH OPERATIONS

JUN 17 2013

Tom Betlach, Director
Arizona Health Care Cost Containment System
801 East Jefferson Street
Phoenix, AZ 85034

Dear Mr. Betlach:

Enclosed is an approval letter from Larry Reed, Director of CMS Division of Pharmacy, for Arizona State Plan Amendment (SPA) 13-004. Copies of the approved State Plan pages are also included. SPA 13-004 was submitted to my office on March 28, 2013 to comply with the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008, which added barbiturates used in the treatment of epilepsy, cancer and chronic mental health disorders and benzodiazepines as categories of drugs Part D plans must cover as of January 1, 2013. This amendment excludes from coverage benzodiazepines for all conditions and barbiturates for those conditions for full benefit dual eligible beneficiaries.

The effective date of this SPA is January 1, 2013. Enclosed are the following approved SPA pages that should be incorporated into your approved State Plan:

- Attachment 3.1-A Limitations, page 9
- Attachment 3.1-A Limitations, page 9(a)

Enclosed are the additional following documents:

- HCFA Form 179
- Approval letter from CMS' Division of Pharmacy

If you have any questions, please contact Tyler Sadwith by phone at (415) 744-3563 or by email at Tyler.Sadwith@cms.hhs.gov.

Sincerely,

/s/

Gloria Nagle, Ph.D., MPA
Associate Regional Administrator
Division of Medicaid & Children's Health Operations

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop S2-14-26
Baltimore, Maryland 21244-1850



Disabled & Elderly Health Programs Group

June 17, 2013

Tom Betlach, Director
Arizona Health Care Cost Containment System
801 East Jefferson Street
Phoenix, AZ 85034

Dear Mr. Betlach:

We have reviewed Arizona's State Plan Amendment (SPA) 13-004, received in the San Francisco Regional Office on March 28, 2013. This amendment proposes to exclude from coverage benzodiazepines for all conditions and barbiturates for the treatment of epilepsy, cancer and chronic mental health disorders for full benefit dual eligibles as Medicare Part D will provide this coverage.

Based on the information provided, we are pleased to inform you that consistent with the regulations at 42 CFR 430.20, SPA 13-004 is approved with an effective date of January 1, 2013. A copy of the signed CMS-179 form, as well as the pages approved for incorporation into the Arizona state plan will be forwarded by the San Francisco Regional Office.

If you have any questions regarding this amendment, please contact Jessica Walker at (410) 786-2457.

Sincerely,

/s/

Larry Reed
Director
Division of Pharmacy

cc: Monica Coury, Arizona Health Care Cost Containment System
Gloria Nagle, ARA, San Francisco Regional Office
Tyler Sadwith, San Francisco Regional Office